SC 13G 1 tm215908d1_sc13g.htm SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Montes Archimedes Acquisition Corp.

(Name of Issuer)

 

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

612657106

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)

 

  ¨ Rule 13d-1(c)

 

  x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 612657106

1.

Names of Reporting Persons

 

Patient Square Capital LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

With:

  5.  

Sole Voting Power

 

10,167,956 (1)

  6.  

Shared Voting Power

 

0

  7.  

Sole Dispositive Power

 

10,167,956 (1)(2)

  8.  

Shared Dispositive Power

 

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

10,167,956 (1)(2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

See footnote (2) below.

11.

Percent of Class Represented by Amount in Row (9)

 

19.8% (1)(2)(3)

12.

Type of Reporting Person (See Instructions)

 

OO

         

2

 

 

CUSIP No. 612657106

1.

Names of Reporting Persons

 

James C. Momtazee

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

With:

  5.  

Sole Voting Power

 

10,167,956 (1)

  6.  

Shared Voting Power

 

0

  7.  

Sole Dispositive Power

 

10,167,956 (1)(2)

  8.  

Shared Dispositive Power

 

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

10,167,956 (1)(2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

See footnote (2) below.

11.

Percent of Class Represented by Amount in Row (9)

 

19.8% (1)(2)(3)

12.

Type of Reporting Person (See Instructions)

 

IN

         

 

(1)

See Item 4. These are the shares of the Issuer’s Class B common stock, which are automatically convertible into shares of the Issuer’s Class A common stock at the time of the Issuer’s initial business combination (the “Business Combination”), or may be converted at any time at the option of the holder, as more fully described under the heading “Description of Securities-Founder Shares” in the Issuer’s registration statement on Form S-1 (File No. 333-248802). Patient Square Capital LLC is the record holder of the shares reported herein. James C. Momtazee is the managing member of Patient Square Capital LLC. As such, they may be deemed to have or share voting and dispositive power over the shares of Class B common stock held directly by Patient Square Capital LLC.

 

(2) Excludes 10,214,265 shares which may be purchased by exercising warrants that are not presently exercisable.

 

(3) Based on 41,071,823 shares of Class A common stock and 10,167,956  shares of Class B common stock issued and outstanding as of November 19, 2020 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2020.

 

3

 

 

Item 1(a). Name of Issuer

 

Montes Archimedes Acquisition Corp. (the “Issuer”)

 

Item 1(b). Address of the Issuer’s Principal Executive Offices

 

724 Oak Grove, Suite 130

Menlo Park, California 94025

 

Item 2(a). Names of Persons Filing

 

Patient Square Capital LLC and James C. Momtazee (collectively, the “Reporting Persons”)

 

Item 2(b). Address of the Principal Business Office, or if none, Residence:

 

724 Oak Grove, Suite 130

Menlo Park, California 94025

 

Item 2(c). Citizenship

 

Patient Square Capital LLC is a limited liability company formed in Delaware. James C. Momtazee is a citizen of the United States.

 

Item 2(d). Title of Class of Securities

 

Class A common stock, $0.0001 par value per share.

 

* The Class A common stock is the class of shares of the Issuer registered pursuant to the Act. The Reporting Persons own shares of Class B common stock. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer’s Business Combination on a one-for-one basis, or may be converted at any time at the option of the holder, subject to certain adjustments. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Issuer’s initial public offering (the “IPO”) and related to the closing of the Business Combination, the ratio at which the shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate 20% of the sum of the sum of all common stock outstanding upon completion of the IPO plus all Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination and any private placement-equivalent warrants issued to Patient Square Capital LLC or its affiliates upon conversion of loans made to the Issuer).

 

Item 2(e). CUSIP Number

 

The CUSIP number for the Class A common stock is 612657106.

 

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.

 

  ¨ (a) Broker or Dealer registered under Section 15 of the Exchange Act.
       
  ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
       
  ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
  ¨ (d) Investment company registered under Section 8 of the Investment Company Act.
       
  ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
       
  ¨ (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
       
  ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
       
  ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
  ¨ (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
       
  ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).

 

4

 

 

Item 4. Ownership

 

The responses to Items 5–11 of the cover pages of this Schedule 13G are incorporated herein by reference.

 

As of December 31, 2020, the Reporting Persons may be deemed to beneficially own 10,167,956 shares of the Issuer’s Class B common stock, representing 19.8% of the total shares of Class A and Class B common stock issued and outstanding. The shares of Class B common stock are automatically convertible into shares of the Issuer’s Class A common stock at the time of the Issuer’s Business Combination on a one-for-one basis, or may be converted at any time at the option of the holder, subject to adjustment, as more fully described under the heading “Description of Securities-Founder Shares” in the Issuer’s registration statement on Form S-1 (File No. 333-248802). The percentage of Class B common stock held by the Reporting Persons is based upon 41,071,823 shares of Class A common stock and 10,167,956 shares of Class B common stock issued and outstanding as of November 19, 2020 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2020.

 

Patient Square Capital LLC is the record holder of the shares reported herein. James C. Momtazee is the managing member of Patient Square Capital LLC. As such, they may be deemed to have or share voting and dispositive power over the shares of Class B common stock held directly by Patient Square Capital LLC.

 

Item 5. Ownership of Five Percent or Less of a Class

 

Not Applicable

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person

 

Not Applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

 

Not Applicable

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable

 

Item 9. Notice of Dissolution of Group

 

Not Applicable

 

Item 10. Certification

 

Not Applicable

 

5

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DATE: February 10, 2021

 

  PATIENT SQUARE CAPITAL LLC,
  a Delaware limited liability company
   
    By: /s/ James C. Momtazee
    Name: James C. Momtazee
    Title: Limited Partner
   
  /s/ James C. Momtazee
  James C. Momtazee

 

6

 

  

EXHIBIT 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Class A common stock, $0.0001 par value per share, of Montes Archimedes Acquisition Corp., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

 

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

 

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 10, 2021.

 

  PATIENT SQUARE CAPITAL LLC,
  a Delaware limited liability company
   
    By: /s/ James C. Momtazee
    Name: James C. Momtazee
    Title: Limited Partner
   
  /s/ James C. Momtazee
  James C. Momtazee

7